Frontiers in Nutrition,
Journal Year:
2022,
Volume and Issue:
9
Published: May 24, 2022
Infants
remain
at
high
risk
for
severe
coronavirus
disease
2019
(COVID-19).
Human
milk
contains
levels
of
protective
SARS
CoV-2
specific
antibodies
post-infection
and
primary
vaccine
series,
but
decline
over
time.
We
hypothesized
that
the
COVID-19
booster
augment
antibody
production
protection
afforded
to
human
milk-fed
infants.
prospectively
enrolled
pregnant
or
lactating
mothers
planning
receive
vaccination.
measured
IgG,
IgA,
IgM
targeting
receptor
binding
domain
within
spike
protein
neutralization
activity
against
in
10
from
pre-COVID-19
series
post-booster
dose.
IgG
increased
significantly
pre-
(median
OD
0.33
vs.
2.02,
P
=
0.002).
The
were
even
higher
than
peak
level
after
(2.02
0.95,
0.03).
increase
IgA
was
not
significant
(0.10
0.33,
0.23).
There
a
strong
correlation
between
paired
maternal
blood
(IgG
rho
0.52,
<
0.001,
0.31,
0.05).
Post-booster
neutralizing
elevated
compared
pre-booster
(66%
12%
inhibition,
elicits
initial
series.
This
finding
suggests
three
doses
mRNA
vaccination
leads
improved
mucosal
response
reinforces
current
guidance
recommending
all
full
courses
with
Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics),
Journal Year:
2025,
Volume and Issue:
70(1), P. 56 - 63
Published: March 6, 2025
Respiratory
mycoplasmosis
and
chlamydia
in
combination
with
COVID-19
children
during
the
pandemic
is
a
significant
concern
structure
of
infectious
morbidity.
Objective
.
The
aim
work
to
identify
features
course
atypical
pathogens.
Materials
methods
uses
an
integrated
approach
analyzing
data
from
clinical,
laboratory
instrumental
examinations
respiratory
comparison
monoinfection
groups
based
on
use
mathematical
modeling.
Results
Since
studied
demonstrated
homogeneity
most
characteristics,
model
for
predicting
risk
combined
infections
was
developed
variety
clinical
data.
Conclusions
Due
high
prevalence
pneumonia
mycoplasmosis,
similarity
key
symptoms
monoinfection,
algorithm
early
differential
diagnosis
combinations
pathogens
has
been
modeling
identification
these
at
prehospital
stage.
Frontiers in Microbiology,
Journal Year:
2025,
Volume and Issue:
16
Published: April 30, 2025
Background
The
clinical
consequences
of
the
co-infection
with
novel
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
and
syncytial
virus
(RSV)
are
not
optimistic.
Nevertheless,
there
is
currently
no
approved
therapeutic
regimen
specifically
targeting
SARS-CoV-2/RSV
co-infection,
existing
monotherapies
showing
limited
efficacy.
According
to
recent
studies,
probenecid
has
both
anti-SARS-CoV-2
anti-RSV
effects.
Therefore,
as
one
probable
molecular
candidate
for
SARS-CoV-2
RSV,
was
researched
in
this
exploration.
Methods
Using
systems
pharmacology
bioinformatics,
we
characterized
targets
associated
treatment
focusing
on
their
biological
functions,
mechanisms
binding
activities.
To
further
validate
these
findings,
conducted
docking,
MD
simulations,
electrostatic
potential
mapping,
SAR
analysis
explore
interactions
between
identified
core
targets.
Results
We
141
that
overlapped
probenecid,
used
shared
construct
a
protein-protein
interaction
(PPI)
network.
Subsequently,
obtained
top
16
hub
namely,
AKT1,
ALB,
EGFR,
CASP3,
CTNNB1,
SRC,
HSP90AA1,
so
on.
enrichment
analysis,
might
affect
inflammation,
immunity,
oxidative
stress,
defenses;
Toll-like
receptor,
TNF,
IL-17,
NOD-like
cytokine-cytokine
among
others.
Additionally,
based
docking
effectively
bound
related
co-infection.
Meanwhile,
according
dynamics
(MD)
simulations
structure-activity
relationship
(SAR)
speculated
SRC
HSP90AA1
more
likely
be
target
proteins
than
other
proteins.
Conclusion
Our
findings
from
bioinformatics
indicate
immune
inflammatory
responses
play
pivotal
role
effects
probenecid.
Infectious
disease-related
pathways
also
contribute
significantly
its
effectiveness
treating
Further
validation
through
analysis.
These
analyses
suggest
This
study
provides
valuable
preliminary
insights
into
It
establishes
strong
foundation
future
research
strategy
JAMA Neurology,
Journal Year:
2022,
Volume and Issue:
80(1), P. 91 - 91
Published: Nov. 7, 2022
Importance
In
2020
during
the
COVID-19
pandemic,
neurologic
involvement
was
common
in
children
and
adolescents
hospitalized
United
States
for
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)–related
complications.
Objective
To
provide
an
update
on
spectrum
of
SARS-CoV-2–related
among
2021.
Design,
Setting,
Participants
Case
series
investigation
patients
reported
to
public
health
surveillance
with
illness
between
December
15,
2020,
31,
2021,
55
US
hospitals
31
states
follow-up
at
hospital
discharge.
A
total
2253
were
enrolled
period.
Patients
suspected
having
multisystem
inflammatory
(MIS-C)
who
did
not
meet
criteria
(n
=
85)
excluded.
(&lt;21
years)
positive
SARS-CoV-2
test
results
(reverse
transcriptase–polymerase
chain
reaction
and/or
antibody)
meeting
MIS-C
or
included
analysis.
Exposure
infection.
Main
Outcomes
Measures
had
signs,
symptoms,
diseases
presentation
hospitalization.
Life-threatening
adjudicated
by
experts
based
clinical
neuroradiological
features.
Type
severity
involvement,
laboratory
imaging
data,
vaccination
status,
discharge
outcomes
(death
survival
new
deficits).
Results
Of
2168
(58%
male;
median
age,
10.3
years),
1435
(66%)
met
MIS-C,
476
(22%)
documented
involvement.
vs
without
older
(median
12
10
more
frequently
underlying
disorders
(107
[22%]
240
1692
[14%]).
Among
those
42
(9%)
developed
life-threatening
conditions,
including
central
nervous
system
infection/demyelination
23;
15
possible/confirmed
encephalitis,
6
meningitis,
1
transverse
myelitis,
nonhemorrhagic
leukoencephalopathy),
stroke
11),
encephalopathy
5),
fulminant
cerebral
edema
2),
Guillain-Barré
1).
Ten
(24%)
survived
deficits
8
(19%)
died.
16
vaccine-eligible
(94%)
unvaccinated.
Conclusions
Relevance
persisted
2021
again
mostly
transient.
Central
accounted
a
higher
proportion
most
may
prevent
some
complications
merits
further
study.
Frontiers in Nutrition,
Journal Year:
2022,
Volume and Issue:
9
Published: May 24, 2022
Infants
remain
at
high
risk
for
severe
coronavirus
disease
2019
(COVID-19).
Human
milk
contains
levels
of
protective
SARS
CoV-2
specific
antibodies
post-infection
and
primary
vaccine
series,
but
decline
over
time.
We
hypothesized
that
the
COVID-19
booster
augment
antibody
production
protection
afforded
to
human
milk-fed
infants.
prospectively
enrolled
pregnant
or
lactating
mothers
planning
receive
vaccination.
measured
IgG,
IgA,
IgM
targeting
receptor
binding
domain
within
spike
protein
neutralization
activity
against
in
10
from
pre-COVID-19
series
post-booster
dose.
IgG
increased
significantly
pre-
(median
OD
0.33
vs.
2.02,
P
=
0.002).
The
were
even
higher
than
peak
level
after
(2.02
0.95,
0.03).
increase
IgA
was
not
significant
(0.10
0.33,
0.23).
There
a
strong
correlation
between
paired
maternal
blood
(IgG
rho
0.52,
<
0.001,
0.31,
0.05).
Post-booster
neutralizing
elevated
compared
pre-booster
(66%
12%
inhibition,
elicits
initial
series.
This
finding
suggests
three
doses
mRNA
vaccination
leads
improved
mucosal
response
reinforces
current
guidance
recommending
all
full
courses
with
